Predicting axillary lymph node metastases in breast cancer patients with tumors under 2 cm in size

Breast Cancer

Volumn 6, Issue 2, 1999, Pages 167-170

  Tsuchiya, Atsuo ^a   Kanno, Masahiko ^a   Zhang, Guo Jun ^a   Sagara, Hiroya ^a   Watanabe, Takanori ^a   Kimijima, Izo ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Axillary lymph node dissection; Breast cancer; T1 tumor; Tumor size

Indexed keywords

EID: 84863267343     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966926     Document Type: Article

References (23)

1. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772, 1981. (Pubitemid 11072899)
2. Carter C, Allen C, Henson D: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989. (Pubitemid 19032001)
3. Chadha M, Chabon AB, Friedmann P, et al: Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer 73:664-667, 1994.
4. Silverstein MJ, Gierson ED, Waisman JR, et al: Axillary lymph node dissection for T1a breast carcinoma; Is it indicated? Cancer 73:664-667, 1994. (Pubitemid 24046609)
5. Harris JR, Lippman ME, Veronesi U, et al: Breast cancer. N Engl J Med 127:392-399, 1992.
6. Giuliano AE, Barth AM, Spivack B, et al: Incidence and predictor of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 183:185-189, 1996. (Pubitemid 26299179)
7. McGee JM, Youmans R, Clingen F, et al: The value of axillary dissection in T1a breast cancer. Am J Surg 172:501-505, 1996. (Pubitemid 26415760)
8. Shetty MR, Reiman HM Jr: Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995. Eur J Surg Oncol 23:139-141, 1997. (Pubitemid 27223007)
9. Silverstein MJ, Gierson ED, Waisman JR, et al: Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 180:700-704, 1995.
10. Silverstein MJ, Gierson ED, Colburn WJ, et al: Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 172:211-214, 1991.
11. Seidman JD, Schnaper LA, Aisner SC: Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 75:65-71, 1995.
12. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-684, 1985.
13. Harris JR, Osteen RT: Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 5:17-21, 1985. (Pubitemid 15163213)
14. Benson EA, Thorogood J: The effect of surgical technique on local recurrence rates following mastectomy. Eur J Surg Oncol 12:267-271, 1986. (Pubitemid 16006972)
15. Cabanes PA, Salmon RJ, Vilcoq JR, et al: Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 339:1245-1248, 1992.
16. Haffty BG, McKhann C, Beinfield M, et al: Breast conservation therapy without axillary dissection; A rational treatment strategy in selected patients. Arch Surg 128:1315-1319, 1993. (Pubitemid 23360023)
17. Cady B: The need to reexamine axillary lymph nodes dissection in invasive breast cancer. Cancer 73:505-508, 1994. (Pubitemid 24046585)
18. Cancer Research Campaign Working Party: Cancer research campaign (King's/Cambridge) trial for early breast cancer; A detailed update at the tenth year. Lancet 2:55-60, 1980.
19. Lythoque JP, Palmer MF: Manchester regional breast study; 5 and 10 year results. Br J Surg 69:693-696, 1982.
20. Clark RM, Wilkinson RH, Mahoney LJ, et al: Breast cancer; A 21 year experience with conservative surgery and radiation. Int J Radiol Oncol Biol Phys 8:967-975, 1982. (Pubitemid 12038674)
21. Early Breast Cancer Trialist Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy; One hundred thirty three randomized trials involving 31,000 recurrence and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
22. Fisher B, Redmond C, Dimitriov N, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who has estrogen receptor negative tumors. N Engl J Med 320:473-478, 1989. (Pubitemid 19062521)
23. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherpay for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997. (Pubitemid 27508191)